NASDAQ$PHAT
Phathom Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Phathom reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
Phathom Pharmaceuticals reported a net loss of $55.0 million for the fourth quarter ended December 31, 2022, compared to a net loss of $35.8 million for the fourth quarter of 2021. Research and development expenses for the fourth quarter 2022 were $15.9 million, and general and administrative expenses were $30.7 million. Cash and cash equivalents were $155.4 million as of December 31, 2022.
- Phathom delivered positive topline results for its third Phase 3 trial, PHALCON-NERD-301, evaluating vonoprazan for non-erosive GERD.
- Phathom reported positive topline results from a Phase 2 proof-of-concept trial for vonoprazan dosed as needed for non-erosive GERD.
- The FDA approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of Helicobacter pylori (H. pylori) infection in adults on May 3, 2022.
- Phathom secured up to $300 million in non-dilutive capital under the terms of its revenue interest financing agreement.
Headline financials
Revenue & EPS history
Phathom · Revenue · Quarterly
$58.3M
Forward guidance
Phathom anticipates generating stability data to support the proposed shelf life of vonoprazan and approval of its erosive esophagitis NDA. They also anticipate product launches in H. pylori and erosive esophagitis and believe they will have sufficient capital to fund operations through 2024.
Tailwinds
- Expectations of generating stability data necessary to support the proposed shelf life of vonoprazan.
- Potential approval of its erosive esophagitis NDA and post approval supplements for its H. pylori NDAs.
- Anticipated product launches in H. pylori and erosive esophagitis.
- Potential of vonoprazan to provide patients with a rapid relief agent to treat non-erosive GERD.
- Belief that Phathom will have sufficient capital to fund operations through 2024.
Headwinds
- Phathom may be unable to generate the required data to meet the acceptable intake of its nitrosamine impurity.
- The FDA may disagree that the existing safety and efficacy data, together with additional data, is sufficient to approve the erosive esophagitis NDA or supplements to the H. pylori NDAs.
- Unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims.
- Phathom’s ability to access additional capital under its term loan facility and royalty interest finance agreements is subject to certain conditions.
- Phathom’s ability to comply with its license agreement with Takeda.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-2.2%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+10.0%
Q1 2023
Best reaction
-22.8%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | +6.9% | -18.6% | |
| Q4 2025 | +9.9% | -10.3% | -14.1% | |
| Q3 2025 | -1.8% | +8.1% | +9.8% | |
| Q1 2025 | -21.7% | -44.1% | -0.9% | |
| Q4 2024 | -3.0% | -21.2% | -19.7% | |
| Q3 2024 | -6.3% | -47.1% | -50.0% | |
| Q2 2024 | +8.7% | +12.6% | +63.9% | |
| Q1 2024 | -5.6% | +2.9% | +5.0% | |
| Q4 2023 | -8.7% | -16.0% | +13.4% | |
| Q3 2023 | -4.0% | -9.2% | +7.8% | |
| Q2 2023 | +3.0% | +2.0% | -15.8% | |
| Q1 2023 | +10.0% | +5.0% | +8.3% | |
| Q4 2022 | -7.1% | -10.0% | -29.9% | |
| Q3 2022 | -9.8% | +4.0% | +5.3% | |
| Q2 2022 | -22.8% | -20.1% | -3.6% | |
| Q1 2022 | -6.3% | -10.5% | -19.7% | |
| Q4 2021 | +2.0% | -4.2% | -24.9% | |
| Q3 2021 | +1.7% | -2.4% | -13.7% | |
| Q2 2021 | +1.5% | -0.1% | +6.6% | |
| Q1 2021 | +6.4% | +0.9% | +5.9% | |
| Q4 2020 | +3.6% | +1.9% | +9.8% | |
| Q3 2020 | -8.6% | -3.0% | +12.6% | |
| Q2 2020 | +5.1% | +12.2% | +5.3% | |
| Q1 2020 | -0.9% | -1.4% | +24.1% | |
| Q4 2019 | -3.2% | -3.2% | +13.5% | |
| Q3 2019 | +6.5% | +9.1% | +9.0% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro